Korro, FDA and Orphan Drug
Hosted on MSN1mon
Korro Bio CFO takes medical leave, interim officers appointedKorro Bio, Inc. (NASDAQ:KRRO), a pharmaceutical company specializing in preparations with a market capitalization of $285 million, announced today that Vineet Agarwal, the company's Chief ...
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...
Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results